A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study

Background The prognosis of acute lymphoblastic leukemia in the elderly is poor. The GRAALL-SA1 phase II, randomized trial compared the efficacy and toxicity of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in patients 55 years or older with Philadelphia chromosome-negative acute lymphoblastic leukemia. Design and Methods Sixty patients received either continuous-infusion doxorubicin (12 mg/m2/day) and continuous-infusion vincristine (0.4 mg/day) on days 1–4 or pegylated liposomal doxorubicin (40 mg/m2) and standard vincristine (2 mg) on day 1, accompanied by dexamethasone, followed at day 28 by a second cycle, reinforced by cyclophosphamide. End-points were safety, outcome and prognostic factors. Results Myelosuppression was reduced in the pegylated liposomal doxorubicin arm with shorter severe neutropenia (P=0.05), shorter severe thrombocytopenia (P=0.03), and fewer red blood cell transfusions (P=0.04). Grade 3/4 infections and Gram-negative bacteremia were reduced in the pegylated liposomal doxorubicin arm (P=0.04 and P=0.02, respectively). There was a trend towards fewer cardiac events among the patients who received pegylated liposomal doxorubicin (1/29 versus 6/31). The complete remission rate was 82% and, with a median follow-up of 4 years, median event-free survival and overall survival were 9 and 10 months, respectively. Despite the better tolerance of pegylated liposomal doxorubicin, no differences in survival were observed between the two arms, due to trends towards more induction refractoriness (17 versus 3%, P=0.10) and a higher cumulative incidence of relapse (52% versus 32% at 2 years, P=0.20) in the pegylated liposomal doxorubicin arm. Conclusions With the drug schedules used in this study, pegylated liposomal doxorubicin did not improve the outcome of elderly patients with acute lymphoblastic leukemia despite reduced toxicities.

[1]  E. Estey,et al.  Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimen , 1994, British journal of haematology.

[2]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[3]  C. Pegelow,et al.  Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia. , 1982, Cancer treatment reports.

[4]  O. Legrand,et al.  Prognostic factors in elderly acute lymphoblastic leukaemia , 1997, British journal of haematology.

[5]  G. Heller,et al.  Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan‐Kettering‐New York‐II protocol , 1993, Cancer.

[6]  R. Bouabdallah,et al.  Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients , 1997, Leukemia.

[7]  M. Bernard,et al.  Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study , 2001, Leukemia.

[8]  P. Piccaluga,et al.  Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma , 2005, Leukemia & lymphoma.

[9]  M. Sack,et al.  Clinical evaluation of long-term, continuous-infusion doxorubicin. , 1983, Cancer treatment reports.

[10]  S. Suciu,et al.  Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. , 2002, Blood.

[11]  K. Remes,et al.  VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? , 1993, Leukemia & lymphoma.

[12]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[14]  H. Heimpel,et al.  Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period. , 1994, Annals of hematology.

[15]  R. Rifkin,et al.  Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma , 2006, Cancer.

[16]  D.,et al.  Regression Models and Life-Tables , 2022 .

[17]  R. Bouabdallah,et al.  Treatment of Acute Lymphoblastic Leukemia in the Elderly: An Evaluation of Interferon Alpha Given as a Single Agent After Complete Remission , 2002, Leukemia & lymphoma.

[18]  R. Carlson,et al.  Continuous infusion or bolus injection in cancer chemotherapy. , 1983, Annals of internal medicine.

[19]  Edward J. Lee,et al.  A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. , 1998, Blood.

[20]  S. Giannouli,et al.  Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. , 2002, Anticancer research.

[21]  M. Offidani,et al.  High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. , 2003, The hematology journal : the official journal of the European Haematology Association.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  A. Delannoy,et al.  Acute lymphoblastic leukemia in the elderly , 1990, European journal of haematology.

[24]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[25]  J. Magaud,et al.  Acute lymphoblastic leukemia in the elderly: The Edouard Herriot hospital experience , 2001, American journal of hematology.

[26]  D. Kontoyiannis,et al.  Glucocorticoids and invasive fungal infections , 2003, The Lancet.

[27]  N. Bown,et al.  Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. , 1992, Blood.

[28]  H. Heimpel,et al.  Acute lymphoblastic leukemia in patients over 59 years of age , 1994, Annals of Hematology.

[29]  B. D. de Pauw,et al.  CELLULAR PHARMACOKINETICS OF DAUNOMYCIN ADMINISTERED AS CONTINUOUS INTRAVENOUS INFUSION IN THE TREATMENT OF ACUTE NON‐LYMPHOCYTIC LEUKAEMIA , 1986, British journal of haematology.

[30]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  K.,et al.  Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. , 1989, Blood.

[32]  F. Mandelli,et al.  Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. , 1995, Leukemia.

[33]  T. Barbui,et al.  Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. , 1996, Leukemia & lymphoma.

[34]  T. Naoe,et al.  [Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia]. , 1999, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[35]  E. Henderson,et al.  Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. , 1984, Blood.

[36]  L. Mele,et al.  Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. , 2000, Haematologica.

[37]  M. Zucchetti,et al.  Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. , 1998, Haematologica.

[38]  E. Estey,et al.  Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Torti,et al.  The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[41]  A. Delannoy,et al.  Acute lymphoblastic leukemia in the elderly. , 2002, The hematology journal : the official journal of the European Haematology Association.